Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GW870086 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| GW870086 2mg | EXPERIMENTAL | GW870086 2mg once daily in the morning for 27 ± 2 days |
| GW870086 4mg | EXPERIMENTAL | GW870086 4mg once daily in the morning for 27 ± 2 days |
| Placebo | PLACEBO_COMPARATOR | Placebo once daily in the morning for 27 ± 2 days |
| GW870086 1mg | EXPERIMENTAL | GW870086 1mg once daily in the morning for 27 ± 2 days |
| GW870086 3mg | EXPERIMENTAL | GW870086 3mg once daily in the morning for 27 ± 2 days |
| Name | Type | Description |
|---|---|---|
| GW870086 2mg | DRUG | oral inhalation |
| GW870086 4mg | DRUG | oral inhalation |
| GW870086 Placebo | DRUG | oral inhalation |
| GW870086 1mg | DRUG | oral inhalation |
| GW870086 3mg | DRUG | oral inhalation |
Inclusion Criteria: * Male or female between 18 and 65 years * A female subject is eligible to participate if she is of: Non-childbearing potential. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to discontinue HRT to allow confirmation of post...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
GW870086 is an investigational small molecule developed by GSK plc for the treatment of asthma. It was studied as an inhaled therapy in a Phase 2 clinical trial that measured changes in forced expiratory volume in 1 second (FEV1), a standard lung function measure, in adult asthma patients.
GW870086 was developed for the treatment of asthma. It was evaluated in a Phase 2 study of adult asthmatics to assess efficacy and dose response on forced expiratory volume in 1 second (FEV1). It is an investigational agent and is not an approved asthma therapy.
GW870086 is developed by GSK plc, which trades under the ticker GSK. GSK sponsored the Phase 2 asthma study of the compound.
GW870086 is in Phase 2 development. One Phase 2 trial has been completed, and no active trials are currently listed. The compound is investigational and has not been approved for any indication.
GW870086 was studied in the completed Phase 2 trial NCT01245426, titled a study in asthmatics to determine the efficacy and dose response of repeat doses of GW870086X on forced expiratory volume in 1 second (FEV1). It enrolled 136 participants across Bulgaria, Germany, and South Africa.